[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100552731":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":27,"centralContacts":27,"locations":27,"responsibleParty":35,"collaborators":27,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":27,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":27,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":27,"overallStatus":58,"whyStopped":27,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":27},{"fullName":5,"class":6},"The First Affiliated Hospital of Nanchang University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Fixed regimen","EXPERIMENTAL","orelabrutinib + FCR\u002FBR",[13,14],"Drug: orelabrutinib","Drug: FCR\u002FBR",{"label":16,"type":17,"description":18,"interventionNames":19},"Control","ACTIVE_COMPARATOR","BTKi chosen by doctors",[20],"Drug: BTK inhibitor",[22,28,31],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","orelabrutinib","orelabrutinib tablets",[9],null,{"type":23,"name":29,"description":29,"armGroupLabels":30,"otherNames":27},"FCR\u002FBR",[9],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":27},"BTK inhibitor","BTK inhibitor choose by physican",[16],{"type":36,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"SPONSOR_INVESTIGATOR","Fei Li","Chief physician","100552731","phase-2-a-practical-clinical-study-comparing-the-fixed-cycle-regimen-containing-orelabrutinib-with-btki-monotherapy-100552731",false,"NCT06476899","A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy","A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy in Previously Untreated CLL\u002FSLL","Inclusion Criteria:\n\n* Age between 18 and 70 years, with no gender restrictions;\n* Patients with CLL\u002FSLL who meet the iwCLL2018 diagnostic criteria;\n* Indications for treatment\n* ECOG performance score of 0-2;\n* Patients are untreated or have not received standardized treatment\n* Before the trial screening, the subject or their legal representative voluntarily signs a written informed consent form, indicating that they understand the purpose of the study and the necessary research steps, and are able to comply with the protocol and follow-up.\n\nExclusion Criteria:\n\n* Has been diagnosed or treated for malignancies other than CLL (including active central nervous system lymphoma) within the past year;\n* there is clinical evidence of Richter transformation;\n* Participant cannot receive or plan to receive another treatment during study participation\n* Other conditions that the investigator considers inappropriate for participation","ALL","18 Years","70 Years",{"count":50,"type":51},60,"ESTIMATED","INTERVENTIONAL",[54],"PHASE2","Prospective, interventional, and practical clinical studies",[57],"CLL\u002FSLL","NOT_YET_RECRUITING","2024-06-21",{"date":61,"type":62},"2024-06-27","ACTUAL",{"date":64,"type":51},"2024-07-24",{"date":66,"type":51},"2026-12-26",{"name":37,"class":6}]